Pharmaceutical stocks faced a downturn following President Trump's announcement of a phased tariff plan on imported generic drugs, leading to notable declines across major companies.
The Nifty Pharma index saw a drop of 1.16%, reversing some of its earlier gains. Notable losses included Lupin, which fell by 3.32%, and other significant players like Piramal Pharma and Aurobindo Pharma, which also experienced declines of over 2%. This trend highlights the immediate market reaction to the proposed tariffs, which could have far-reaching implications for the industry.
According to the announcement, generic medicines imported into the U.S. will remain tariff-free for two years starting August 2026. After this period, tariffs will increase incrementally, reaching 200% by August 2029. This policy aims to incentivize pharmaceutical companies to relocate their generic drug manufacturing to the U.S., imposing penalties on those who do not comply. While the focus is on generics, the policy does not affect patented or innovative medicines.
This tariff strategy places significant pressure on Indian pharmaceutical companies, which are major suppliers of generics to the U.S. market. Given that the U.S. is the largest export destination for India's pharmaceutical sector, the proposed tariffs could reshape production and investment strategies in the long term, making it a critical factor for stakeholders in the industry.